Survival time of circulating long-acting thyroid stimulator in neonatal thyrotoxicosis: implications for diagnosis and therapy of the disorder.
Survival time of circulating long-acting thyroid stimulator in neonatal thyrotoxicosis: implications for diagnosis and therapy of the disorder.
复制标题
循环长效甲状腺刺激剂在新生儿甲状腺毒症中的生存时间：对该疾病的诊断和治疗的影响。
DOI：
10.1542/peds.36.6.869
复制
发表时间：
1965
期刊：
影响因子：
8
通讯作者：
Joseph P. Kriss
中科院分区：
文献类型：
--
作者：
P. Sunshine;Howard Kusumoto;Joseph P. Kriss
我们描述了一例新生儿甲状腺功能亢进症，发展为室上性心动过速、甲状腺肿和眼眶周围水肿。婴儿和母亲的血清中都含有长效甲状腺刺激物(LATS)。虽然母亲的血清中的LATS水平保持不变，但婴儿的血清中的LATS水平迅速下降。计算出婴儿血清中LATS的生物半衰期为6天，到21日龄时检测不到LATS活性。根据这些发现，在出生后不久就开始的抗甲状腺治疗在第38天停止，没有复发甲亢的体征或症状。
除了常规的抗甲状腺药物治疗甲亢外，当新生儿或母亲的血清LATS滴度分别很高时，还可以考虑对母亲进行换血和产前皮质类固醇治疗。
We have described an infant with neonatal thyrotoxicosis who developed supraventricular tachycandia, goiter, and periorbital edema. Both the baby's and mother's sera contained the long-acting thyroid stimulator (LATS). While the level of LATS remained unchanged in the serum of the mother, it rapidly fell in the serum of the infant. The biological half-life of LATS in the infant's serum was calculated to be 6 days, and by the age of 21 days no LATS activity could be detected. Based on these findings, antithyroidal treatment which had been instituted soon after birth was discontinued on the thirty-eighth day without recurrence of signs or symptoms of thyrotoxicosis.
In addition to conventional antithyroid therapy for thyrotoxicosis, exchange transfusion and prenatal corticosteroid therapy of the mother may be considered when neonatal or maternal serum LATS titers, respectively, are very high.